Rajamannan Nalini M, Greve Anders M, Moura Luis M, Best Patricia, Wachtell Kristian
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Expert Rev Cardiovasc Ther. 2015 Apr;13(4):355-67. doi: 10.1586/14779072.2015.1025058.
SALTIRE and RAAVE were the first two studies to evaluate the use of statin therapy for impeding calcific aortic valve disease (CAVD). This review presents the findings of low-density lipoprotein (LDL)-density-radius theory as tested using the combined results from the SALTIRE and RAAVE studies. Patients who received statin therapy had a greater degree of LDL cholesterol lowering, seen as the % change in LDL (47 vs 2%, p = 0.012), which in itself was significantly associated with a lesser change in aortic valve area (AVA; p < 0.001 and R(2) = 0.27). The percent change in the AVA for the treated patients was 5% and 15% for the nontreated patients (p = 0.579 and R(2) = 0.03). In summary, these published findings suggest that when applying the LDL-density-radius theory, which combines the cellular biology and the hemodynamics as defined by the continuity equation for AVA, there may be a role for lipid-lowering therapy in contemporary patients with calcific aortic valve disease (CAVD).
SALTIRE和RAAVE是最早评估使用他汀类药物治疗以延缓钙化性主动脉瓣疾病（CAVD）的两项研究。本综述展示了利用SALTIRE和RAAVE研究的综合结果对低密度脂蛋白（LDL）-密度-半径理论进行测试的结果。接受他汀类药物治疗的患者低密度脂蛋白胆固醇降低程度更大，表现为LDL的百分比变化（47%对2%，p = 0.012），这本身与主动脉瓣面积（AVA）的较小变化显著相关（p < 0.001且R² = 0.27）。治疗患者的AVA百分比变化为5%，未治疗患者为15%（p = 0.579且R² = 0.03）。总之，这些已发表的研究结果表明，当应用结合细胞生物学和由AVA连续性方程定义的血流动力学的LDL-密度-半径理论时，降脂治疗在当代钙化性主动脉瓣疾病（CAVD）患者中可能具有作用。
